Mycenax Biotech (ROCO:4726) Research & Development: NT$75.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4726 Mycenax Biotech Inc ROCO:4726
43 GF Score
Price NT$24.50
GF Value NT$47.88
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mycenax Biotech Research & Development?

Mycenax Biotech ROCO:4726 -4.67% 43 Research & Development is NT$75.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4726 with a GF Score™ of 43/100 and a GF Value™ of NT$47.88 (Possible Value Trap). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Mycenax Biotech's Research & Development for the three months ended in Dec. 2025 was NT$20.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$75.9 Mil.

Mycenax Biotech  (ROCO:4726) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mycenax Biotech Research & Development Related Terms

Mycenax Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Mycenax Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mycenax Biotech Research & Development Chart

Mycenax Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.13 144.00 75.81 78.19 75.91

Mycenax Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.73 17.45 19.00 19.50 19.96
ROCO:4726
43GF Score
Mycenax Biotech Inc ROCO:4726
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mycenax Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$75.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$75.9 Mil mean?
Mycenax Biotech (ROCO:4726) has a Research & Development of NT$75.9 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Mycenax Biotech and its competitors.
Is Mycenax Biotech's Research & Development too high?
Mycenax Biotech's current Research & Development is NT$75.9 Mil. Overall, Mycenax Biotech has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mycenax Biotech's Research & Development compare to VRTX and REGN?
Mycenax Biotech's Research & Development of NT$75.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Mycenax Biotech and its competitors. Mycenax Biotech's current Research & Development is NT$75.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mycenax Biotech stock overvalued right now?
Based on GuruFocus' analysis, Mycenax Biotech (ROCO:4726) is currently considered Possible Value Trap. The stock's GF Value™ is NT$47.88, compared to a current price of NT$24.50 — trading 48.8% below its estimated fair value. The current Research & Development is NT$75.9 Mil. Mycenax Biotech's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Mycenax Biotech (ROCO:4726), the current Research & Development is NT$75.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mycenax Biotech (ROCO:4726) Overvalued in 2026?

Based on GuruFocus' analysis, Mycenax Biotech stock appears to be undervalued. The current stock price of NT$24.50 is trading 48.8% below its estimated GF Value™ of NT$47.88. GuruFocus considers Mycenax Biotech to be Possible Value Trap.

Key valuation signals for ROCO:4726:

  • Research & Development: NT$75.9 Mil
  • GF Value™: NT$47.88 vs. price of NT$24.50 (48.8% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4726 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mycenax Biotech Business Description

Address No. 66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards. The company's main operating region is located in Taiwan.
43GF Score

Get the complete analysis for ROCO:4726

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$24.50
Price
NT$47.88
GF Value